Currently enrolling! How does the pill form of this drug class compare to injected GLP-1s?

Intarcia just announced exciting results for ITCA 650 , a small implanted device to treat type 2 diabetes. The tiny device is implanted under the skin just once or twice...

Enrolling now – how this implanted CGM compares to current CGM offerings.

Plus, a massive $2 billion investment in new production facilities!

Clinical trial currently enrolling for type 2 diabetes – find out if you qualify for this study.

New trial testing the inhaled, ultra-rapid insulin in 4-17 year olds.

Enrolling at over 140 sites worldwide. Can it reduce A1c and insulin use and improve time-in-range?

Find nearby T1D, T2D, gestational diabetes, and complications trials with new clinical trials matching tool launched by JDRF and TrialReach

A six-month study of Diasome Pharmaceuticals’ HDV Insulin in Type 1 Diabetes

Recruiting participants in Boston at the Joslin Diabetes Center

What are the implications for other injected GLP-1 agonist drugs?

Program designed for Medicaid and uninsured individuals at risk for diabetes. Omada Health recently announced the launch of Prevent for Underserved Populations. The new...

Seeking participants with type 2 diabetes to investigate the effects of semaglutide on heart health

Comparing Medtronic’s MiniMed 670G to injections and pumps in people with type 1 diabetes, with and without CGM; enrollment to open in May at some trial locations

A real-world trial in 3,000+ participants currently enrolling participants with type 2 diabetes

A six-week study of Tandem’s first automated insulin delivery device with Dexcom’s G5 CGM

Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA

The S-ICD is an FDA-approved device that can prevent sudden cardiac arrest; this trial is testing it in people with diabetes who’ve had prior heart attacks with...

The new CITY trial will enroll 200 young adults with type 1 diabetes to study the impact of CGM use on diabetes, especially when A1c levels are high.The new CITY trial...

Recruiting 1,200 people with type 2 diabetes from diverse ethnic and racial backgrounds for a more thorough understanding of Soliqua’s impact on diabetes management